Kala Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call
October 29 2020 - 8:00AM
Business Wire
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical
company focused on the discovery, development and commercialization
of innovative therapies for diseases of the eye, today announced
that it will report third quarter 2020 financial results on
Thursday, November 5, 2020. Management will host a conference call
and live audio webcast to discuss these results and provide a
business update at 8:00 a.m. ET.
The dial-in numbers to access the conference call are
866-300-4091 (domestic) or 703-736-7433 (international) using the
conference ID 9199546. To access a live webcast and subsequent
archived recording of the call, please visit the “Investors &
Media” section on the Kala website at http://kalarx.com/.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the discovery,
development, and commercialization of innovative therapies for
diseases of the eye. Kala has applied its AMPPLIFY® mucus
penetrating particle Drug Delivery Technology to a corticosteroid,
loteprednol etabonate (LE), designed for ocular applications,
resulting in the October 2020 approval of EYSUVISTM (loteprednol
etabonate ophthalmic suspension) 0.25% for the short-term (up to
two weeks) treatment of signs and symptoms of dry eye disease and
the January 2019 launch of INVELTYS® (loteprednol etabonate
ophthalmic suspension) 1% for the treatment of post-operative
inflammation and pain following ocular surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029005165/en/
Loraine Spreen loraine.spreen@kalarx.com 857-277-4842
Hannah Deresiewicz hannah.deresiewicz@sternir.com
212-362-1200
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From May 2024 to Jun 2024
KALA BIO (NASDAQ:KALA)
Historical Stock Chart
From Jun 2023 to Jun 2024